Nanjing Leads Biolabs' Research Results Selected for 2026 Oncology Meeting Presentations
() -- Six of Nanjing Leads Biolabs' (HKG:9887) latest research results were selected to be presented at the 2026 annual meeting of the European Society for Medical Oncology. Two were chosen for oral presentation, while four were selected for poster presentations covering extrapulmonary neuroendocrine carcinoma, biliary